Aclaris Therapeutics Inc (ACRS)
Healthcare
Biotechnology
5.20 $
-2.3%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Aclaris Therapeutics Inc (ACRS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 81.0% of the shares are freely tradable; institutional investors hold 79.7%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
79.7%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
2.3%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
81.0%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
7.3%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
140Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BML Capital Management LLC | 10.20 | 14,250,000 | +0.0 | 03/31/2026 |
| Deep Track Capital, LP | 6.69 | 9,345,000 | +0.0 | 03/31/2026 |
| BlackRock Inc | 5.30 | 7,407,065 | +8.8 | 03/31/2026 |
| RA Capital Management, LLC | 4.87 | 6,804,072 | +0.0 | 03/31/2026 |
| Vivo Capital, LLC | 4.77 | 6,666,666 | -25.0 | 03/31/2026 |
| Vanguard Group Inc | 4.66 | 6,502,080 | -0.2 | 12/31/2025 |
| Vanguard Capital Management, LLC | 3.70 | 5,167,469 | +0.0 | 03/31/2026 |
| Frazier Life Sciences Management, L.P. | 3.53 | 4,925,374 | +0.0 | 03/31/2026 |
| Rock Springs Capital Management LP | 3.20 | 4,472,650 | +0.4 | 03/31/2026 |
| Decheng Capital LLC | 2.89 | 4,041,736 | +0.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.